Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01915173 · ClinicalTrials.gov registry record · NA
Response to Supplement and Placebo in GERD
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT01915173 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 24 participants.
The verdict
NCT01915173, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effects of a widely available over the counter supplement marketed for heartburn symptoms on symptoms and health-related quality of life in patients with gastroesophageal reflux disease (GERD). This study is designed as a pilot trial to assess safety and feasibility and to provide preliminary estimates of effect sizes.
Interventions
- DRUG Placebo
- DRUG Supplement
- BEHAVIORAL Expanded Interview
- BEHAVIORAL Standard Interview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01915173
The ClinicalTrials.gov registry entry for NCT01915173 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01915173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01915173 about?
NCT01915173 is a clinical study titled "Response to Supplement and Placebo in GERD". The purpose of this study is to investigate the effects of a widely available over the counter supplement marketed for heartburn symptoms on symptoms and health-related quality of life in patients with gastroesophageal reflux disease (GERD). This study is designed as a pilot trial to assess safety a...
What is the current status of trial NCT01915173?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2013-06. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01915173?
The interventions under investigation include: Placebo (DRUG), Supplement (DRUG), Expanded Interview (BEHAVIORAL), Standard Interview (BEHAVIORAL).
Who is sponsoring clinical trial NCT01915173?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.